Levomefolic acid (
INN, also known as L-5-MTHF, L-methylfolate and L-5-methyltetrahydrofolate and (6S)-5-methyltetrahydrofolate, and (6S)-5-MTHF) is the primary biologically active form of
folate used at the cellular level for
DNA reproduction, the
cysteine cycle and the regulation of
homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the
blood–brain barrier. In the cell, L-methylfolate is used in the
methylation of
homocysteine to form
methionine and
tetrahydrofolate (
THF). THF is the immediate acceptor of one carbon unit for the synthesis of
thymidine-
DNA,
purines (
RNA and
DNA) and
methionine. The un-methylated form,
folic acid (vitamin B9), is a synthetic form of
folate, and must undergo enzymatic reduction by
dihydrofolate reductase (
DHFR) to become biologically active.[1]
It is synthesized in the absorptive cells of the small intestine from polyglutamylated dietary
folate. It is a methylated derivative of
tetrahydrofolate.
L-Methylfolate is water-soluble and primarily excreted via the kidneys. In a study of 21 subjects with coronary artery disease, peak plasma levels were reached in one to three hours following
oral or
parenteral administration. Peak concentrations were found to be more than seven times higher than
folic acid (129
ng/ml vs. 14.1 ng/ml).[3]
Patients at risk for vitamin B12 deficiency should consult with their medical provider prior to taking L-Methylfolate. The interrelationship between these two vitamins (L-Methylfolate and B12) is best explained by the methyl trap hypothesis.[4][5]
Research suggests that levomefolic acid (L-methylfolate) taken with a
first-lineantidepressant[6] provides a modest
adjunctive antidepressant effect for individuals who do not respond or have only a partial therapeutic response to
SSRI or
SNRI medication,[7][8] and might be a more cost-effective adjunctive agent than
second-generation antipsychotics.[9]
Cardiovascular disease and cancer
Levomefolic acid (and folic acid in turn) has been proposed for treatment of cardiovascular disease[10][11] and advanced cancers such as breast and
colorectal cancers.[12] It bypasses several metabolic steps in the body and better binds
thymidylate synthase with
FdUMP, a metabolite of the drug
fluorouracil.
Patent issues
In March 2012,
Merck & Cie of
Switzerland,
Pamlab LLC (maker of
Metanx and
Cerefolin, Neevo DHA, and Deplin), and South Alabama Medical Science Foundation (SAMSF) (the plaintiffs) filed a complaint in the
United States District Court for the Eastern District of Texas against four defendants: Macoven Pharmaceuticals (owned by Pernix Therapeutics), Gnosis SpA of Italy, Gnosis U.S.A and Gnosis Bioresearch Switzerland. The plaintiffs alleged that the defendants infringed on several of the plaintiffs' patents.[13] The Macoven products named in the suit are: "Vitaciric-B", "ALZ-NAC", "PNV DHA", and l-methylfolate calcium (levomefolate calcium).[14]
In September 2012, the same three plaintiffs filed a complaint requesting that the
International Trade Commission begin a 19 U.S.C.§ 1337 investigation of the same four defendants. The complaint states that Gnosis' "Extrafolic-S" and products which are made from it, infringe upon three of their patents: US 5997915, US 6673381, and US 7172778.[15]
Formulations
Levomefolate calcium, a calcium
salt of levomefolic acid is sold under the brand name Metafolin[16] and incorporated in Deplin.[17] Levomefolate magnesium is a magnesium salt of levomefolic acid, manufactured as DeltaFolate, a primary ingredient in EnLyte.[18]
^Ströhle A, Wolters M, Hahn A (June 2005). "Folic acid and colorectal cancer prevention: molecular mechanisms and epidemiological evidence (Review)". International Journal of Oncology. 26 (6): 1449–64.
doi:
10.3892/ijo.26.6.1449.
PMID15870856.
^"Metafolin". MilliporeSigma. Retrieved 28 November 2022. Metafolin® is our manufactured calcium salt of L-5-methyltetrahydrofolic or L-methylfolate. ... The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.
^"DEPLIN®". For Healthcare Professionals. Retrieved 28 November 2022.
Brockton NT (October 2006). "Localized depletion: the key to colorectal cancer risk mediated by MTHFR genotype and folate?". Cancer Causes & Control. 17 (8): 1005–16.
doi:
10.1007/s10552-006-0051-5.
PMID16933051.
S2CID20394873.
Stahl SM (October 2007). "Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent". CNS Spectrums. 12 (10): 739–44.
doi:
10.1017/S1092852900015418.
PMID17934378.
S2CID27000937.